01 feb: Selskabsmeddelelse nr. 1/2017 - Regnskabsmeddelelse, Q1 2016/17
01 feb: Afholdt generalforsamling 2017
01-02-2017 12:00:45

Coloplast delivers satisfactory Q1 interim results in line with expectations

Relateret indhold
21 jul - 
Fredagens aktier: Mærsk, Novo og FLSmidth sendte C20 ti..
21 jul - 
Aktier/middag: FLSmidth får stryg og tager bunden i C20
13 jul - 
Torsdagens aktier: Nets i uvant rekordrolle i roligt ma..
Relateret debat
12 jul - 
Du er formentlig glad for, du ikke fik sat den short ;)..
09 jul - 
Jeg trækker bare Coloplast frem i lyset, fordi je..
09 jul - 
Coloplast er ikke en særlig sexet aktie, så jeg holder ..

In Q1, Coloplast delivered organic revenue growth of 6% and an EBIT margin of 33% at constant exchange rates. The results are in line with expectations.

Coloplast delivered organic growth of 6% in the first three months of the 2016/17 financial year, increasing revenue measured in Danish kroner by 3% to DKK 3,755m. EBIT increased by 3% to reach DKK 1,226m, while the profit for the period was up by 15% to DKK 946m.

Coloplast continued to generate growth in all business areas in the first quarter, delivering organic growth in Ostomy Care at 6%, Continence Care at 5%, Wound & Skin Care at 5% and Urology Care at 8%.

In Continence Care, Coloplast recently launched a new flexible catheter for men, the SpeediCath Flex. The product is now on the market in 11 countries. In addition, in Wound & Skin Care, the Biatain Silicone Sizes & Shapes product portfolio had been launched in eight countries on 1 January. Both launches have received very positive feedback from users and healthcare professionals.

Geographically, Europe was the main growth driver overall, delivering 6% organic growth, with sales growth in the UK and France standing out. Other developed markets produced 4% growth, while Emerging Markets contributed 7%.

"We delivered satisfactory results in the first quarter of the year, supported by a particularly strong performance of our European business. Growth in the US was affected by inventory reductions of large distributors. Inventory levels are now back to normal, and we expect this to drive favourable sales growth developments in the coming quarters," says Lars Rasmussen, CEO of Coloplast.

In a move to support the overall ambition of bringing innovative products and services to the US market, Coloplast acquired US distributor Comfort Medical in November. The acquisition was approved in late December, and the process of integrating the company has now been set in motion.

Coloplast continues to expect an organic revenue growth of 7-8% at constant exchange rates. Coloplast now expects organic revenue growth of 7-8% in Danish kroner (DKK) following the acquisition of Comfort Medical and developments in the British pound and the US dollar. Coloplast continues to expect the EBIT margin to be 33-34% at constant exchange rates and about 33% in DKK.

         Maria Lindeberg

         Senior Media Relations Manager

         +45 49 11 30 95

         dkmalg@coloplast.com

         

         Ellen Bjurgert

         Director, Investor Relations

         +45 49 11 33 76

         dkebj@coloplast.com

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: Novo og Genmab presser dansk marked i rødt

24-07-2017 11:27:49
Det danske aktiemarked er præget af kursfald mandag, hvor Novo Nordisk, Genmab og Pandora er under størst pres blandt de største aktier.Omkring middagstid falder C20 Cap-indekset 0,8 pct. til 1159,07. Det er primært en svækkelse af dollar og justeringer af kursmål, som er i fokus, inden den danske regnskabssæson for alvor kommer op i gear i starten af august.- Dollar er blevet svækket på det senes..

Carlsberg/Berenberg: Kursmålet løftes til 652 kr. - gentager "hold"

24-07-2017 08:13:02
Carlsberg gør sig fortsat kun fortjent til anbefalingen "hold" hos den tyske bank Berenberg, der dog sætter et nyt kursmål på 652 kr. mod tidligere 577 kr.Det sker i en dugfrisk brancheanalyse, hvor bankens bryggerianalytikere har set nærmere på det vietnamesiske marked.Berenberg fastholder i analysen også anbefalingen "hold" af Heineken, mens Anheuser-Busch Inbev stadig foretrækkes med anbefaling..

Vestas-rival får vindmølleordre til projekt i Indonesien i hus

21-07-2017 16:09:14
Tysk-spanske Siemens Gamesa har landet en ordre på 72 megawatt (MW) fordelt over 20 vindmøller af typen SWT-3,6-130 til et projekt i Indonesien.Projektet, som hedder Tolo 1, bliver udviklet af det lokale energiselskab Equis Energy, der også står som køber af møllerne. De skal efter planen installeres mod slutningen af 2017, hvorefter idriftsættelse kan indledes tidligt i 2018. Sammen med ordren ha..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Novo og Genmab presser dansk marked i rødt
2
Genmab/Carnegie: Mere end fordobler kursmål og sænker anbefaling
3
Mandagens aktier: Novo og Novozymes faldt mest i presset marked
4
Aktier/tendens: Analytikerne ser med mildere øjne på Carlsberg og GN
5
Volkswagen holder ekstraordinært møde under kartelmistanke

Relaterede aktiekurser

Coloplast B A/S 543,00 -1,6% Fald i aktiekurs
Coloplast 85,70 3,3% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. juli 2017 02:35:01
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170720.2 - EUROWEB2 - 2017-07-25 02:35:01 - 2017-07-25 02:35:01 - 1 - Website: OKAY